Mölnlycke to establish R&D innovation unit in AstraZeneca’s BioVentureHub
Mölnlycke, a world-leading medical products and solutions company, is pleased to announce the establishment of an R&D innovation unit in the BioVentureHub at AstraZeneca Gothenburg. The aim is to find new innovative solutions that will benefit both healthcare professionals and patients.
The new unit will build on Mölnlycke’s cell biology and analytical chemistry capabilities, and develop innovative advanced wound care and surgical solutions along the entire continuum of care – from prevention to post-acute settings.
“We are very excited to be part of AstraZeneca’s BioVentureHub, as it offers a unique opportunity for us to collaborate with AstraZeneca’s world-class scientists and benefit from their state-of-the-art facilities and infrastructure while developing new advanced wound care and surgical solutions for our customers. We’re also looking forward to exploring collaboration opportunities with the other BioVentureHub companies,” comments Richard Twomey, CEO of Mölnlycke.
Magnus Björsne, CEO for AstraZeneca’s BioVentureHub , says, “It’s fantastic that a well-established, global, medical solutions company like Mölnlycke wants to be part of our innovation experiment. Besides further strengthening the life science ecosystem in West Sweden, this collaboration offers new opportunities to work with innovation across different value chains. AstraZeneca is continuously looking for new ways to deliver drugs to the right place in the body. Preventing pressure ulcers and infections related to diabetes and metabolic diseases is just one area where we could collaborate more closely to benefit patients.”
The agreement was signed by Barry McBride, Executive Vice-President for R&D at Mölnlycke, and Jan-Olof Jacke, President of AstraZeneca Sweden, during the AstraZeneca Exchange 2017 event .
Contact at Mölnlycke:
Bodil Czarnecki, Global Manager, Corporate Communications
+46 (0) 739 41 25 37
Contact at AstraZeneca's BioVentureHub:
Notes for the editors:
Mölnlycke is a world leading medical solutions company. Our purpose is to advance performance in healthcare across the world. That is why we aspire to equip everybody in healthcare with solutions to achieve the best outcomes. We develop and bring to market innovative wound care and surgical solutions along the entire continuum of care – from prevention to post-acute settings. Our solutions provide value for money, supported by clinical and health economic evidence.
Mölnlycke was founded in 1849. Nowadays, our solutions are available in around 100 countries; we are the number one global provider of advanced wound care and single-use surgical products; and we are Europe’s largest provider of customized trays. Our headquarters are in Gothenburg, Sweden and we have about 7,500 employees around the world. Learn more at molnlycke.com .
About AstraZeneca’s BioVentureHub:
AstraZeneca established the BioVentureHub in 2014 as an open innovation ecosystem to further strengthen competitiveness and dynamism in the Scandinavian life science industry. Based on an innovative public-private partnership model and located at the heart of AstraZeneca Gothenburg, the BioVenturehub gives emerging biotech/medtech companies and academic groups from Sweden and abroad a unique opportunity to co-locate with - and tap into - the power of AstraZeneca’s world-class scientists and state-of-the-art lab facilities and infrastructure, and with each other. See azbioventurehub.com